Checklist for Prescribers:

Initiation of Emtricitabine/Tenofovir disoproxil Accord for Pre-exposure Prophylaxis (PrEP)

Instructions:
Complete checklist at each visit and file in individual's medical record

I have completed the following prior to prescribing Emtricitabine/Tenofovir disoproxil Accord for a pre-exposure prophylaxis (PrEP) indication for the individual who is about to start or is taking Emtricitabine/Tenofovir disoproxil for a PrEP indication:

Lab Tests/Evaluation

- ❑ Completed high risk evaluation of uninfected individual
- ❑ Confirmed a negative HIV-1 test immediately prior to initiating Emtricitabine/Tenofovir disoproxil Accord for a PrEP indication
  - If clinical symptoms consistent with acute viral infection are present and recent (<1 month) exposure is suspected, delay starting PrEP for at least 1 month and reconfirm HIV-1 status or use a test approved by the competent authority as an aid in the diagnosis of HIV-1 infection, including acute or primary HIV-1 infection. (Note: Emtricitabine/Tenofovir disoproxil Accord for a PrEP indication is contraindicated in individuals with unknown HIV-1 status or who are HIV-1 positive)
- ❑ Performed HBV screening test
- ❑ Confirmed estimated creatinine clearance (CrCl) >60 mL/min prior to initiation and periodically during treatment. In patients at risk for renal dysfunction, assess estimated CrCl, serum phosphorus, urine glucose, and urine protein before initiation of Emtricitabine/Tenofovir disoproxil Accord and periodically while Emtricitabine/Tenofovir disoproxil Accord is being used. If a decrease in estimated CrCl is observed in uninfected individuals while using Emtricitabine/Tenofovir disoproxil Accord for a PrEP indication, evaluate potential causes and reassess potential risks and benefits of continued use.
- ❑ Confirmed that the uninfected individual at high risk is not taking other HIV-1 medications or HBV medications
- ❑ Evaluated risk/benefit for women who may be pregnant or may want to become pregnant

Counselling

- ❑ Discussed known safety risks with use of Emtricitabine/Tenofovir disoproxil Accord for a PrEP indication
- ❑ Counselled on the importance of scheduled follow-up every 2 to 3 months, including regular HIV-1 screening tests (at least every 3 months), while taking Emtricitabine/Tenofovir disoproxil Accord for a PrEP indication to reconfirm HIV-1–negative status
- ❑ Discussed the importance of discontinuing Emtricitabine/Tenofovir disoproxil Accord for a PrEP indication if seroconversion has occurred, to reduce the development of resistant HIV-1 variants

accord

- ❑ Counselled on the importance of adherence to daily dosing schedule
- ❑ Counselled that Emtricitabine/Tenofovir disoproxil Accord for a PrEP indication should be used only as part of a comprehensive prevention strategy
- ❑ Educated on practicing safer sex consistently and using condoms correctly
- ❑ Discussed the importance of the individual knowing their HIV-1 status and, if possible, that of their partner(s)
- ❑ Discussed the importance of and performed screening for sexually transmitted infections (STIs), such as syphilis and gonorrhea, that can facilitate HIV-1 transmission
- ❑ Offered HBV vaccination as appropriate
- ❑ Provided education on where information about Emtricitabine/Tenofovir disoproxil Accord for a PrEP indication can be accessed
- ❑ Discussed potential adverse reactions

Follow-up

- ❑ Discussed known safety risks with use of Emtricitabine/Tenofovir disoproxil Accord for a PrEP indication
- ❑ Counselled on the importance of scheduled follow-up every 2 to 3 months, including regular HIV-1 screening tests (at least every 3 months), while taking Emtricitabine/Tenofovir disoproxil Accord for a PrEP indication to reconfirm HIV-1–negative status Counselled on the importance of scheduled follow-up every 2 to 3 months, including regular HIV-1 screening tests (at least every 3 months), while taking Emtricitabine/Tenofovir disoproxil Accord for a PrEP indication to reconfirm HIV-1–negative status
- ❑ Discussed the importance of discontinuing Emtricitabine/Tenofovir disoproxil Accord for a PrEP indication if seroconversion has occurred, to reduce the development of resistant HIV-1 variants
- ❑ Counselled on the importance of adherence to daily dosing schedule
- ❑ Counselled that Emtricitabine/Tenofovir disoproxil Accord for a PrEP indication should be used only as part of a comprehensive prevention strategy
- ❑ Educated on practicing safer sex consistently and using condoms correctly
- ❑ Discussed the importance of the individual knowing their HIV-1 status and, if possible, that of their partner(s)
- ❑ Discussed the importance of and performed screening for sexually transmitted infections (STIs), such as syphilis and gonorrhea, that can facilitate HIV-1 transmission
- ❑ Offered HBV vaccination as appropriate
- ❑ Provided education on where information about Emtricitabine/Tenofovir disoproxil Accord for a PrEP indication can be accessed
- ❑ Discussed potential adverse reactions

accord